DOCSLIB.ORG

21 CFR Ch. II (4–1–96 Edition) § 1308.34

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

§ 1308.34 21 CFR Ch. II (4±1±96 Edition) the date on which it will take effect. following the procedures set forth in The Administrator shall permit any in- paragraph (d) of this section for han- terested person to file written com- dling an application for an exemption ments on or objections to the order which has been accepted for filing. within 60 days of the date of publica- tion of his order in the FEDERAL REG- [56 FR 42936, Aug. 30, 1991; 57 FR 10815, Mar. 31, 1992] ISTER. If any such comments or objec- tions raise significant issues regarding § 1308.34 Exempt anabolic steroid any finding of fact or conclusion of law products. upon which the order is based, the Ad- ministrator shall immediately suspend The following anabolic steroid con- the effectiveness of the order until he taining compounds, mixtures, or may reconsider the application in light preparations have been exempted by of the comments and objections filed. the Administrator from application of Thereafter, the Administrator shall re- sections 302 through 309 and 1002 instate, revoke, or amend his original through 1004 of the Act (21 U.S.C. 822± order as he determines appropriate. 829 and 952±954) and §§ 1301.24, 1301.31, (e) The Administrator may revoke 1301.32, and 1301.71 through 1301.76 of any exemption granted pursuant to this chapter for administrative pur- section 1903(a) of Public Law 101±647 by poses only: TABLE OF EXEMPT ANABOLIC STEROID PRODUCTS Trade name Company NDC No. Form Ingredients Quantity Androgyn L.A. .............. Forest Pharma- 0456±1005 ......... Vial ............ Testosterone enanthate 90 mg/ml ceuticals, St. Louis, Estradiol valerate ......... 4 mg/ml MO. Andro-Estro 90±4 ......... Rugby Laboratories, 0536±1605 ......... Vial ............ Testosterone enanthate 90 mg/ml Rockville Centre, NY. Estradiol valerate ......... 4 mg/ml depANDROGYN .......... Forest Pharma- 0456±1020 ......... Vial ............ Testosterone cypionate 50 mg/ml ceuticals, St. Louis, Estradiol cypionate ...... 2 mg/ml MO. DEPO±T.E. .................. Quality Research 52765±257 ......... Vial ............ Testosterone cypionate 50 mg/ml Pharm., Carmel, IN. Estradiol cypionate ...... 2 mg/ml depTESTROGEN ......... Martica Pharma- 51698±257 ......... Vial ............ Testosterone cypionate 50 mg/ml ceuticals, Phoenix, Estradiol cypionate ...... 2 mg/ml AZ. Duomone ..................... Wintec Pharmaceutical, 52047±360 ......... Vial ............ Testosterone enanthate 90 mg/ml Pacific, MO. Estradiol valerate ......... 4 mg/ml DURATESTRIN ........... W.E. Hauck, 43797±016 ......... Vial ............ Testosterone cypionate 50 mg/ml Alpharetta, GA. Estradiol cypionate ...... 2 mg/ml DUO±SPAN II .............. Primedics Laboratories, 0684±0102 ......... Vial ............ Testosterone cyplonate 50 mg/ml Gardena, CA. Esterified cypionate ..... 2 mg/ml Estratest ....................... Solvay Pharma- 0032±1026 ......... TB ............. Esterified estrogens ..... 1.25 mg ceuticals, Marletta, Methyltestosterone ...... 2.5 mg GA. Estratest HS ................. Solvay Pharma- 0032±1023 ......... TB ............. Esterified estrogens ..... 0.625 mg ceuticals, Marletta, Methyltestosterone ...... 1.25 mg GA. PAN ESTRA TEST ...... Pan American Labs, 0525±0175 ......... Vial ............ Testosterone cypionate 50 mg/ml Covington, LA. Estradiol cypionate ...... 2 mg/ml Premarin with Ayerst Labs. Inc., New 0046±0879 ......... TB ............. Conjugated estrogens 1.25 mg Methyltestosterone. York, NY. Methyltestosterone ...... 10.0 mg Premarin with Ayerst Labs. Inc., New 0046±0878 ......... TB ............. Conjugated estrogens 0.625 mg Methyltestosterone. York, NY. Methyltestosterone ...... 5.0 mg Synovex H Pellets in Syntex Animal Health, ............................ Drum ......... Testosterone propio- 25 mg. process. Palo Alto, CA. nate. 2.5 mg. Estradiol benzoate ....... Synovex H Pellets in Syntex Animal Health, ............................ Drum ......... Testosterone propio- 10 parts. process granulation. Palo Alto, CA. nate. 1 part. Estradiol benzoate ....... TEST±ESTRO Rugby Laboratories, 0536±9470 ......... Vial ............ Testosterone cypionate 50 mg/ml Cypionates. Rockville Centre, NY. Estradiol cypionate ...... 2 mg/ml Testagen ...................... Clint Pharmaceuticals, 55553±257 ......... Vial ............ Testosterone cypionate 50 mg/ml. Nashville, TN. Estradiol cypionate ...... 2 mg/ml. Testosterone Cyp 50 I.D.E.-Interstate, Amity- 0814±7737 ......... Vial ............ Testosterone cypionate 50 mg/ml Estradiol Cyp 2. ville, NY. Estradiol cypionate ...... 2 mg/ml 182 VerDate 14<JUN>96 10:36 Jul 12, 1996 Jkt 167073 PO 00000 Frm 00179 Fmt 8010 Sfmt 8010 C:\CFR\21V9C2.TXT pfrm13 Food and Drug Administration, HHS § 1308.44 TABLE OF EXEMPT ANABOLIC STEROID PRODUCTSÐContinued Trade name Company NDC No. Form Ingredients Quantity Testosterone Best Generics, No. 54274±530 ......... Vial ............ Testosterone cypionate 50 mg/ml CypionateÐEstradiol Miami Beach, FL. Estradiol cypionate ...... 2 mg/ml Cypionate Injection. Testosterone Goldline Labs, Ft. Lau- 0182±3069 ......... Vial ............ Testosterone cypionate 50 mg/ml. CypionateÐEstradiol derdale, FL. Estradiol cypionate ...... 2 mg/ml. Cypionate Injection. Testosterone Schein Pharma- 0364±6611 ......... Vial ............ Testosterone cypionate 50 mg/ml CypionateÐEstradiol ceuticals, Port Wash- Estradiol cypionate ...... 2 mg/ml Cypionate Injection. ington, NY. Testosterone Steris Labs. Inc., Phoe- 0402±0257 ......... Vial ............ Testosterone cypionate 50 mg/ml CypionateÐEstradiol nix, AZ. Estradiol cypionate ...... 2 mg/ml Cypionate Injection. Testosterone The Upjohn Co., Kala- 0009±0253 ......... Vial ............ Testosterone cypionate 50 mg/ml. CypionateÐEstradiol mazoo, MI. Estradiol cypionate ...... 2 mg/ml. Cypionate Injection. Testosterone Goldline Labs, Ft. Lau- 0182±3073 ......... Vial ............ Testosterone enanthate 90 mg/ml. EnanthateÐEstradiol derdale, FL. Estradiol valerate ......... 4 mg/ml. Valerate Injection. Testosterone Schein Pharma- 0364±6618 ......... Vial ............ Testosterone enanthate 90 mg/ml EnanthateÐEstradiol ceuticals, Port Wash- Estradiol valerate ......... 4 mg/ml Valerate Injection. ington, NY. Testosterone Steris Labs. Inc., Phoe- 0402±0360 ......... Vial ............ Testosterone enanthate 90 mg/ml EnanthateÐEstradiol nix, AZ. Estradiol valerate ......... 4 mg/ml Valerate Injection. Tilapia Sex Reversal Zeigler Brothers, Inc., ............................ Plastic Methyltestosterone fish 60 mg/1 kg. Feed (Investigational). Gardners, PA. Bags. feed. [56 FR 42937, Aug. 30, 1991, as amended at 57 FR 55091, Nov. 24, 1992; 58 FR 16773, Mar. 31, 1993; 58 FR 34708, June 29, 1993] HEARINGS § 1308.43 Waiver or modification of Rules. § 1308.41 Hearings generally. The Administrator or the presiding In any case where the Administrator officer (with respect to matters pend- shall hold a hearing on the issuance, ing before him) may modify or waive amendment, or repeal of rules pursuant any rule in this part by notice in ad- to section 201 of the Act, the proce- vance of the hearing, if he determines dures for such hearing and accompany- that no party in the hearing will be un- ing proceedings shall be governed gen- duly prejudiced and the ends of justice erally by the rulemaking procedures will thereby be served. Such notice of set forth in the Administrative Proce- modification or waiver shall be made a dure Act (5 U.S.C. 551±559) and specifi- part of the record of the hearing. cally by section 201 of the Act (21 U.S.C. 811), by §§ 1308.42±1308.51, and by § 1308.44 Initiation of proceedings for §§ 1316.41±1316.67 of this chapter. rulemaking. § 1308.42 Purpose of hearing. (a) Any interested person may sub- mit a petition to initiate proceedings If requested by any interested person for the issuance, amendment, or repeal after proceedings are initiated pursu- of any rule or regulation issuable pur- ant to § 1308.44, the Administrator shall hold a hearing for the purpose of re- suant to the provisions of section 201 of ceiving factual evidence and expert the Act. opinion regarding the issues involved (b) Petitions shall be submitted in in the issuance, amendment or repeal quintuplicate to the Administrator in of a rule issuable pursuant to section the following form: 201(a) of the Act (21 U.S.C. 811(a)). Ex- ÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐÐ tensive argument should not be offered (Date) into evidence but rather presented in ADMINISTRATOR, DRUG ENFORCEMENT opening or closing statements of coun- ADMINISTRATION sel or in memoranda or proposed find- Department of Justice, ings of fact and conclusions of law. Washington, DC 20537. 183 VerDate 14<JUN>96 10:36 Jul 12, 1996 Jkt 167073 PO 00000 Frm 00180 Fmt 8010 Sfmt 8010 C:\CFR\21V9C2.TXT pfrm13.
Recommended publications
  • PPE Requirements Hazardous Drug Handling

    PPE Requirements Hazardous Drug Handling

    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
  • Comparison of the Effects of High Dose Testosterone and 19-Nortestosterone to a Replacement Dose of Testosterone on Strength and Body Composition in Normal Men

    Comparison of the Effects of High Dose Testosterone and 19-Nortestosterone to a Replacement Dose of Testosterone on Strength and Body Composition in Normal Men

    J. Steroid Biochem. Molec. Biol. Vol. 40, No. 4-6, pp. 607~12, 1991 0960-0760/91 $3.00 + 0.00 Printed in Great Britain Pergamon Press plc COMPARISON OF THE EFFECTS OF HIGH DOSE TESTOSTERONE AND 19-NORTESTOSTERONE TO A REPLACEMENT DOSE OF TESTOSTERONE ON STRENGTH AND BODY COMPOSITION IN NORMAL MEN KARL E. FRIEDL,* JOSEPH R. DETTORI, CHARLES J. HANNAN JR, TROY H. PATIENCE and STEPHENR. PLYMATE Exercise Physiology Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA and Department of Clinical Investigation, Madigan Army Medical Center, Tacoma, WA, U.S.A. Summary--We examined the extent to which supraphysiological doses of androgen can modify body composition and strength in normally virilized men. In doubly blind tests, 30 healthy young men received testosterone enanthate (TE) or 19-nortestosterone decanoate (ND), at 100mg/wk or 300mg/wk for 6 weeks. The TE-100mg/wk group served as replacement dose comparison, maintaining pretreatment serum testosterone levels, while keeping all subjects blinded to treatment, particularly through reduction in testicular volumes. Isokinetic strength measurements were made for the biceps brachii and quadriceps femoris muscle groups before treatment and 2-3 days after the 6th injection. Small improvements were noted in all groups but the changes were highly variable; a trend to greater and more consistent strength gain occurred in the TE-300mg/wk group. There was no change in weight for TE-100 mg/wk but an average gain of 3 kg in each of the other groups. No changes in 4 skinfold thicknesses or in estimated percent body fat were observed.
  • Steroids 78 (2013) 44–52

    Steroids 78 (2013) 44–52

    Steroids 78 (2013) 44–52 Contents lists available at SciVerse ScienceDirect Steroids journal homepage: www.elsevier.com/locate/steroids Alternative long-term markers for the detection of methyltestosterone misuse ⇑ C. Gómez a,b, O.J. Pozo a, J. Marcos a,b, J. Segura a,b, R. Ventura a,b, a Bioanalysis Research Group, IMIM-Hospital del Mar, Barcelona, Spain b Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain article info abstract Article history: Methyltestosterone (MT) is one of the most frequently detected anabolic androgenic steroids in doping Received 21 May 2012 control analysis. MT misuse is commonly detected by the identification of its two main metabolites Received in revised form 28 September excreted as glucuronide conjugates, 17a-methyl-5a-androstan-3a,17b-diol and 17a-methyl-5b-andro- 2012 stan-3a,17b-diol. The detection of these metabolites is normally performed by gas chromatography–mass Accepted 10 October 2012 spectrometry, after previous hydrolysis with b-glucuronidase enzymes, extraction and derivatization Available online 2 November 2012 steps. The aim of the present work was to study the sulphate fraction of MT and to evaluate their potential to improve the detection of the misuse of the drug in sports. MT was administered to healthy volunteers Keywords: and urine samples were collected up to 30 days after administration. After an extraction with ethyl ace- Methyltestosterone Sulphate tate, urine extracts were analysed by liquid chromatography tandem mass spectrometry using electro- Metabolism spray ionisation in negative mode by monitoring the transition m/z 385 to m/z 97. Three diol sulphate LC–MS/MS metabolites (S1, S2 and S3) were detected.
  • TESTOSTERONE and ANABOLIC STEROIDS Summary Testosterone Is a Hormone Naturally Produced by the Body

    TESTOSTERONE and ANABOLIC STEROIDS Summary Testosterone Is a Hormone Naturally Produced by the Body

    FactSHEET TESTOSTERONE AND ANABOLIC STEROIDS Summary Testosterone is a hormone naturally produced by the body. Low levels of testosterone can cause symptoms of fatigue, malaise, loss of sex drive, and loss of muscle tissue. These symptoms can often be treated with synthetic testosterone. Anabolic steroids are compounds related to testosterone. Using synthetic testosterone or anabolic steroids may help people with HIV-related wasting gain weight, especially muscle mass. What is testosterone? Sometimes HIV-positive men develop low testosterone levels which can cause symptoms Although it is usually thought of as a male of fatigue, muscle wasting, low (or no) sex hormone, women’s bodies also make drive, impotence, and loss of facial or body testosterone, but at much lower levels than hair. This condition is called hypogonadism. men’s. Testosterone has two different effects on Hormone replacement therapy with synthetic the body: anabolic effects which promote growth testosterone may help to relieve those and muscle building, and androgenic effects symptoms. which develop the male sex organs and secondary sex characteristics such as deepening HIV-positive women may also develop low of the voice and growth of facial hair. testosterone levels and experience symptoms of fatigue, loss of sex drive, and a decreased sense of well-being. Because the androgenic What are anabolic steroids? (masculinizing) effects of testosterone and Anabolic steroids are synthetic compounds anabolic steroids can be permanent, that resemble the natural hormone researchers have been cautious about studying testosterone. Makers of anabolic steroids these drugs in women. change the testosterone molecule slightly to 2. To treat weight loss change the balance of androgenic and anabolic effects, which can allow these drugs to build Anabolic steroids can be used in order to build muscle with fewer masculinizing effects.
  • Degradation of Doping-Relevant Steroids by Rh. Erythropolis

    Degradation of Doping-Relevant Steroids by Rh. Erythropolis

    In: W Schänzer, H Geyer, A Gotzmann, U Mareck (eds.) Recent Advances In Doping Analysis (15). Sport und Buch Strauß - Köln 2007 J. Grosse1), C. Rautenberg1), L. Wassill2), D. Ganghofner2), D. Thieme3) Degradation of doping-relevant Steroids by Rh. Erythropolis 1) Institute of Doping Analysis and Sports Biochemistry, D-01731 Kreischa, Germany 2) Amplex Diagnostics GmbH, D-80337 Munich, Germany 3) Institute of Legal Medicine, D-80337 Munich, Germany Introduction Former studies have shown that steroids are potential substrates for microorganisms [1]. As an example, the degradation of testosterone induced by Rhodococcus erythropolis was observed. The formation of 4-androstene-3,17-dione, 1,4-androstadiene-3,17-dione (boldione) and 1,4-androstadiene-17β-hydroxy-3-one (boldenone) was confirmed [2]. Consequently a potential endogenous origin of boldenone and its metabolites has to be taken into consideration for the evaluation of routine doping control samples revealing the presence of these substances at low concentration level [3, 4]. This work presents results obtained from further studies related to the microbial conversion of steroid substrates being relevant in doping analysis. For this purpose incubation by Rh. erythropolis was applied to examine the influence of structural variations (A/B-ring structure, substitution at position 17, conjugation) on the initial steps of the degradation pathway. Experimental Rh. erythropolis culture grown on agar plate “Mueller-Hinton” was utilised. Altogether 16 substrates (see table 1) were examined in this study. The experiments were carried out in a blank urine of a male infant spiked with 1 µg/mL of the selected substrate. Two aliquots of each sample were prepared, one control without addition and one „active“ sample with addition of bacteria solution, and incubated at 30°C for 24 hours.
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom

    Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom

    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
  • Testosterone, Injectable

    Testosterone, Injectable

    Clinical Criteria Subject: Testosterone, Injectable Document #: ING-CC-0026 Publish Date: 06/10/201909/23/2019 Status: ReviewedRevised Last Review Date: 03/18/201908/16/2019 Table of Contents Overview Coding References Clinical criteria Document history Overview This document addresses indications for the intramuscular (IM) and subcutaneous (SC) administration of testosterone injectables for the treatment of hormone deficient conditions. The following testosterone injection agents are included: • Testosterone cypionate intramuscular: Depo-Testosterone, generic testosterone cypionate • Testosterone enanthate: o Intramuscular: generic testosterone enanthate o Subcutaneous: Xyosted (auto-injector) • Testosterone undecanoate intramuscular: Aveed Testosterone is an androgen hormone responsible for normal growth and development of male sex characteristics. In certain medical conditions such as hypogonadism, the endogenous level of testosterone falls below normal levels. Primary hypogonadism includes conditions such as testicular failure due to cryptorchidism, bilateral torsion, orchitis, or vanishing testis syndrome; bilateral orchidectomy; and inborn errors in the biosynthesis of testosterone. Secondary hypogonadism, also called hypogonadotropic hypogonadism includes conditions such as gonadotropin-releasing hormone (GnRH) deficiency or pituitary-hypothalamic injury resulting from tumors, trauma, surgery, or radiation. In 2015, the Endocrine Society added the following amended recommendations: • Men with metabolic syndrome, who were previously unexamined by the 2010 Endocrine Society Clinical Practice Guidelines, may benefit from testosterone replacement therapy (TRT) based on improvements in biometrics and insulin sensitivity. Effects of TRT on similar endpoints in men with type 2 diabetes mellitus remain unclear; • Effects of TRT on erectile function, even in men refractory to phosphodiesterase type 5 inhibitors, and on quality of life in men with erectile dysfunction remain inconclusive (Seftel, 2015).
  • Anabolic Steroids/Androgens Pa Summary

    Anabolic Steroids/Androgens Pa Summary

    ANABOLIC STEROIDS/ANDROGENS PA SUMMARY PREFERRED Anadrol-50, Danazol, Fluoxymesterone, Methitest, Oxandrolone, Testosterone Cypionate Injection, Testosterone Enanthate Injection NON-PREFERRED Android, Testred LENGTH OF AUTHORIZATION: Varies NOTE: All preferred and non-preferred agents require prior authorization. See PA criteria labeled “Topical Testosterone” for Androderm, Androgel, Striant, and Testim. The criteria details below are for the outpatient pharmacy program. If an injectable medication is being administered in a physician’s office then the criteria information below does not apply. Instead, the physician’s office must bill this drug through the DCH physician’s injectable program and not the outpatient pharmacy program. Information regarding the physician’s injectable program can be located at www.mmis.georgia.gov. PA CRITERIA: For Anadrol-50 Approvable for the following diagnoses: anemia caused by deficient red blood cell production, acquired or congenital aplastic anemia, myelofibrosis, hypoplastic anemia due to administration of myelotoxic drugs Also approvable for HIV or AIDS wasting when significant weight loss is documented in members currently receiving nutritional support For Danazol Approvable for the following diagnoses: endometriosis, fibrocystic breast disease, hereditary angioedema For Fluoxymesterone, Methyltestosterone (Android, Methitest, Testred), Testosterone Cypionate or Enanthate Injection Approvable in male members 12 years of age or older for the following diagnoses: primary hypogonadism, secondary
  • Effects of Supraphysiological Doses of Steroids on the Left Ventricle of Sedentary Mice: Morphometric Analysis

    Effects of Supraphysiological Doses of Steroids on the Left Ventricle of Sedentary Mice: Morphometric Analysis

    Published online: 2019-03-13 THIEME Original Article 91 Effects of Supraphysiological Doses of Steroids on the Left Ventricle of Sedentary Mice: Morphometric Analysis Érika Larissa Poscidônio de Souza1 Rodrigo Leandro Dias1 Raíssa Santiago Rios1 Tânia Martins Vieira1 Bruno Damião1 Wagner Costa Rossi Junior1 Alessandra Esteves1 1 Department of Anatomy, Universidade Federal de Alfenas, Address for correspondence Alessandra Esteves, PhD, Departmento Alfenas, MG, Brazil de Anatomia, Universidade Federal de Alfenas. Rua Gabriel Monteiro da Silva, n°700, Centro, Alfenas, MG, Brazil, CEP 37130-820 J Morphol Sci 2019;36:91–96. (e-mail: [email protected]). Abstract Anabolic androgenic steroids (AAS) are synthetic compounds derived from testosterone, which are widely used in supraphysiological doses by people seeking an aesthetic effect. The objective of the present experiment was to evaluate the possible morphometric changes in the cardiac left ventricle caused by the administration of supraphysiological doses of the anabolic steroids testosterone cypionate and stanozolol in the hearts of young sedentary mice, to serve as a comparative parameter with young mice that were submitted to exercise. We have used 60 hearts of sedentary young Swiss mice, aged 90 days old (young-adult), with a body weight between 40 and 50 g. The animals were divided into three groups: the control group, the testosterone cypionate group, and the stanozolol group. For the analysis, 10 distinct sections of the apex, of the middle region, and of the base of the heart were selected, followed by an optical microscope measurement with a 2.5x magnification. The results obtained show an increase in both myocardial thickness and Keywords left ventricular cavity diameter in the two groups of male animals in relation to the control ► heart group; however, in females, an increase in the thickness of the left ventricular myocardium ► morphometric was observed only for the stanozolol group.
  • Pharmacology/Therapeutics II Block III Lectures 2013-14

    Pharmacology/Therapeutics II Block III Lectures 2013-14

    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
  • Supraphysiological Doses of Performance Enhancing Anabolic-Androgenic Steroids Exert Direct Toxic Effects on Neuron-Like Cells

    Supraphysiological Doses of Performance Enhancing Anabolic-Androgenic Steroids Exert Direct Toxic Effects on Neuron-Like Cells

    ORIGINAL RESEARCH ARTICLE published: 09 May 2013 CELLULAR NEUROSCIENCE doi: 10.3389/fncel.2013.00069 Supraphysiological doses of performance enhancing anabolic-androgenic steroids exert direct toxic effects on neuron-like cells John R. Basile1,2, Nada O. Binmadi 1,3, Hua Zhou1, Ying-Hua Yang1, Antonio Paoli 4 and Patrizia Proia1,5* 1 Department of Oncology and Diagnostic Sciences, University of Maryland Dental School, Baltimore, MD, USA 2 Marlene and Stuart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA 3 Department of Oral Basic and Clinical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia 4 Department of Biomedical Sciences, University of Padova, Padova, Italy 5 Department of Sports Science (DISMOT), University of Palermo, Palermo, Italy Edited by: Anabolic-androgenic steroids (AAS) are lipophilic hormones often taken in excessive Chao Deng, University of quantities by athletes and bodybuilders to enhance performance and increase muscle Wollongong, Australia mass. AAS exert well known toxic effects on specific cell and tissue types and organ Reviewed by: systems. The attention that androgen abuse has received lately should be used as an Agata Copani, University of Catania, Italy opportunity to educate both athletes and the general population regarding their adverse Aram Megighian, University of effects. Among numerous commercially available steroid hormones, very few have been Padua, Italy specifically tested for direct neurotoxicity. We evaluated the effects of supraphysiological *Correspondence: doses of methandienone and 17-α-methyltestosterone on sympathetic-like neuron cells. Patrizia Proia, Department of Sports Vitality and apoptotic effects were analyzed, and immunofluorescence staining and Science (DISMOT), University of Palermo, Via Eleonora Duse 2, western blot performed.
  • JPET #105668 1 Induction of Rat Intestinal P-Glycoprotein By

    JPET #105668 1 Induction of Rat Intestinal P-Glycoprotein By

    JPET Fast Forward. Published on June 1, 2006 as DOI: 10.1124/jpet.106.105668 JPETThis Fast article Forward. has not been Published copyedited and on formatted. June 1, The 2006 final asversion DOI:10.1124/jpet.106.105668 may differ from this version. JPET #105668 1 Induction of rat intestinal p-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin. Carolina I. Ghanem, Paula C. Gómez, María C. Arana, María Perassolo, Griselda Delli Carpini, Marcelo G. Luquita, Luis M. Veggi, Viviana A. Catania, Downloaded from Laura A. Bengochea and Aldo D. Mottino jpet.aspetjournals.org at ASPET Journals on October 2, 2021 Cátedra de Fisiopatología. Departamento de Ciencias Biológicas. Facultad de Farmacia y Bioquímica. Universidad de Buenos Aires. Buenos Aires. Argentina (CIG, PCG, MCA, MP, GDC, LAB). Instituto de Fisiología Experimental, Facultad de Ciencias Bioquímicas y Farmacéuticas. Universidad Nacional de Rosario. Rosario. Argentina (MGL, LMV, VAC, ADM). Copyright 2006 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on June 1, 2006 as DOI: 10.1124/jpet.106.105668 This article has not been copyedited and formatted. The final version may differ from this version. JPET #105668 2 Running title: Effect of spironolactone on P-gp expression and activity. Author for correspondence: Aldo D. Mottino, PhD Instituto de Fisiología experimental Facultad de Ciencias Bioquímicas y Farmacéuticas, UNR. Suipacha 570. (S2002LRL)-Rosario ARGENTINA Downloaded from TE: 54-341-4305799 FAX: 54-341-4399473 E-mail: [email protected] jpet.aspetjournals.org Text pages: 28 Tables: 0 Figures: 4 at ASPET Journals on October 2, 2021 References: 39 Words in Abstract: 238 Words in Introduction: 501 Words in Discussion: 857 ABBREVIATIONS P-gp - P-glycoprotein; Mdr1 - multidrug resistance protein 1; MDR1 - human multidrug resistance protein 1; SL - spironolactone; Mrp2 - Multidrug resistance- associated protein 2; BBM - brush border membrane.